Who buys CBAY stock?
Apr 08, 2022 · Real-time trade and investing ideas on CymaBay Therapeutics Inc CBAY from the largest community of traders and investors.
Are CymaBay Therapeutics insiders selling or buying stock?
Mar 29, 2022 · CymaBay Therapeutics' stock was trading at $1.54 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CBAY shares have increased by 111.0% and is now trading at $3.25. View which stocks have been most impacted by COVID-19.
How much is a share of Cymabay worth?
Find real-time CBAY - Cymabay Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business.
When is CymaBay Therapeutics'next quarterly earnings announcement?
CBAY , 12H Long PennyStock101 Premium Average analysts price target $2.31 11.3% short interest CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need.
Is CBAY a good stock to invest in?
The financial health and growth prospects of CBAY, demonstrate its potential to underperform the market. It currently has a Growth Score of C. Recent price changes and earnings estimate revisions indicate this would not be a good stock for momentum investors with a Momentum Score of F.
Why is CBAY stock dropping?
What happened. Shares of CymaBay Therapeutics ( CBAY 3.09% ) fell over 76% today after the company announced that it was halting the development of its lead drug candidate, seladelpar, in primary biliary cholangitis (PBC).Nov 25, 2019
What is the target price for CBAY?
Stock Price Target CBAYHigh$14.00Median$11.00Low$9.00Average$11.38Current Price$3.25
Will CymaBay Therapeutics stock go up?
Cymabay Therapeutics Inc (NASDAQ:CBAY) The 8 analysts offering 12-month price forecasts for Cymabay Therapeutics Inc have a median target of 11.00, with a high estimate of 14.00 and a low estimate of 9.00. The median estimate represents a +245.91% increase from the last price of 3.18.
Is Cbak a buy?
The CBAK Energy Technology Inc. stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock.
What does CymaBay therapeutics do?
We are a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic diseases that have high unmet medical need through a pipeline of innovative therapies.
Is CymaBay Therapeutics a buy right now?
6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last year. There are currently 5 buy...
How has CymaBay Therapeutics' stock price been impacted by COVID-19?
CymaBay Therapeutics' stock was trading at $1.54 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organizati...
When is CymaBay Therapeutics' next earnings date?
CymaBay Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022. View our earnings forecast for...
How were CymaBay Therapeutics' earnings last quarter?
CymaBay Therapeutics, Inc. (NASDAQ:CBAY) announced its earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.33...
What price target have analysts set for CBAY?
6 analysts have issued twelve-month price targets for CymaBay Therapeutics' stock. Their forecasts range from $7.00 to $14.00. On average, they exp...
Who are CymaBay Therapeutics' key executives?
CymaBay Therapeutics' management team includes the following people: Sujal Shah , President, Chief Executive Officer & Director Daniel Menold ,...
Who are some of CymaBay Therapeutics' key competitors?
Some companies that are related to CymaBay Therapeutics include PMV Pharmaceuticals (PMVP) , Arcutis Biotherapeutics (ARQT) , MorphoSys (MOR) ,...
What other stocks do shareholders of CymaBay Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Sorrento Therap...
What is CymaBay Therapeutics' stock symbol?
CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."
Is CymaBay Therapeutics a buy right now?
What stocks does MarketBeat like better than CymaBay Therapeutics?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last twelve months. There are currently 7 buy ratings and 1 strong buy rating for the stock.
Are investors shorting CymaBay Therapeutics?
Wall Street analysts have given CymaBay Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but CymaBay Therapeutics wasn't one of them.
When is CymaBay Therapeutics' next earnings date?
CymaBay Therapeutics saw a drop in short interest during the month of July. As of July 30th, there was short interest totaling 3,210,000 shares, a drop of 46.0% from the July 15th total of 5,940,000 shares. Based on an average trading volume of 700,200 shares, the short-interest ratio is presently 4.6 days.
How were CymaBay Therapeutics' earnings last quarter?
CymaBay Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.#N#View our earnings forecast for CymaBay Therapeutics.
How has CymaBay Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?
CymaBay Therapeutics, Inc. (NASDAQ:CBAY) released its quarterly earnings results on Thursday, August, 12th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.27) by $0.07.#N#View CymaBay Therapeutics' earnings history.
What price target have analysts set for CBAY?
CymaBay Therapeutics' stock was trading at $1.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CBAY stock has increased by 152.6% and is now trading at $3.89.#N#View which stocks have been most impacted by COVID-19.
CBAY Stock Chart
8 Wall Street analysts have issued 12-month target prices for CymaBay Therapeutics' stock. Their forecasts range from $7.00 to $12.00. On average, they anticipate CymaBay Therapeutics' share price to reach $10.13 in the next twelve months.
Ideas
Looking for price to reject key level and and start to reject trendline and start making new higher higher and contiue to the upside.
Were Hedge Funds Right About CymaBay Therapeutics Inc (CBAY)?
Looking for price to reject key level and and start to reject trendline and start making new higher higher and contiue to the upside.
New Strong Sell Stocks for July 20th
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]
We Think CymaBay Therapeutics (NASDAQ:CBAY) Can Afford To Drive Business Growth
AEVA, BIDU, CBAY, DRNA and RACE have been added to the Zacks Rank #5 (Strong Sell) List on July 20, 2021.
CymaBay Therapeutics Inc. (CBAY) Q1 2021 Earnings Call Transcript
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Is CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Popular Amongst Institutions?
Joining me on the call today are Sujal Shah, chief executive officer; Dr.
5 Disruptive Biotech Stocks With Solid Long-Term Potential
A look at the shareholders of CymaBay Therapeutics, Inc. ( NASDAQ:CBAY ) can tell us which group is most powerful...
CymaBay Therapeutics (NASDAQ:CBAY) Is In A Good Position To Deliver On Growth Plans
Here we discuss five biotech stocks - EDIT, VRTX, NTLA, CBAY, MRNS - that could prove to be great investments in the long run.
Signals & Forecast
Just because a business does not make any money, does not mean that the stock will go down. Indeed, CymaBay...
Support, Risk & Stop-loss
Mostly positive signals in the chart today. The Cymabay Therapeutics Inc stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average.
Is Cymabay Therapeutics Inc stock A Buy?
Cymabay Therapeutics Inc finds support from accumulated volume at $3.96 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.